^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults

Published date:
10/22/2020
Excerpt:
At a median follow-up of 18 months, overall survival was 95% and disease-free survival was 88%; disease-free survival was lower among patients who had an IKZF1 deletion plus additional genetic aberrations (CDKN2A or CDKN2B, PAX5, or both [i.e., IKZF1plus])....first-line treatment with dasatinib and blinatumomab...
DOI:
10.1056/NEJMoa2016272